ReviewCancers2026
Uncovering the Role of Small and Intermediate-Length Non-Coding RNAs in Glioma Pathogenesis and Prognosis.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most prevalent and aggressive primary tumors of the central nervous system (CNS), with glioblastoma demonstrating particularly poor survival rates despite multimodal treatment approaches. The extensive molecular heterogeneity and resistance to conventional therapies highlight the urgent need for novel biomarkers and therapeutic targets. Non-coding RNAs (ncRNAs), transcripts that do not encode proteins, have emerged as crucial regulators of gene expression and cellular homeostasis in both normal and malignant contexts. Their dysregulation contributes to key oncogenic processes, including uncontrolled proliferation, apoptosis, evasion, invasion, and therapeutic resistance. Small and intermediate-sized are strong candidates for biomarkers due to their high abundance and relative stability. Previous reviews on ncRNAs highlight the numerous roles of microRNAs, long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) in gliomas. Here, we focus specifically on small and intermediate-length non-coding RNAs, including transfer RNAs (tRNAs) and tRNA-derived fragments (tRFs or tsRNAs), small nucleolar RNAs (snoRNAs), vault RNAs (vRNAs or vtRNAs), small nuclear RNAs (snRNAs) and mitochondrial tRNAs (mt-tRNAs). Recent studies suggest that these various non-coding RNAs participate in diverse aspects of glioma biology, including regulation of gene expression and modulation of metabolic and immune pathways, and correlate with tumor grade and molecular subtype. In this review, we summarize current evidence regarding the expression profiles and functional roles of small and intermediate-length non-coding RNAs in glioma tumorigenesis, progression, and therapeutic response. The differential expression of many of these ncRNAs in gliomas implies their involvement in both tumor-suppressive and oncogenic processes. A deeper understanding of these molecules may provide valuable insights into glioma biology and reveal novel biomarkers for diagnosis, prognosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.